Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

PURPOSE: This phase I study was conducted to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B-cell malignancies (multiple myeloma [MM], indolent lymphoma, Waldenstrom's macroglobulinemia, and mantle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Holkova, Beata, Kmieciak, Maciej, Perkins, E. Brent, Bose, Prithviraj, Baz, Rachid C., Roodman, G. David, Stuart, Robert K., Ramakrishnan, Viswanathan, Wan, Wen, Peer, Cody J, Dawson, Jana, Kang, Loveleen, Honeycutt, Connie, Tombes, Mary Beth, Shrader, Ellen, Weir-Wiggins, Caryn, Wellons, Martha, Sankala, Heidi, Hogan, Kevin T., Colevas, A. Dimitrios, Doyle, L. Austin, Figg, William D., Coppola, Domenico, Roberts, John D., Sullivan, Daniel, Grant, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4233160/
https://ncbi.nlm.nih.gov/pubmed/25248382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0805
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados